News
November 17, 2025
Investor
Notice Regarding the Disposal of Treasury Shares as Restricted Stock Compensation 
November 13, 2025
Research and Development
Pharma Foods Partners with The University of Tokyo For Next-Generation Antibody Drug Discovery ～A Leap Forward with AI and Advanced Molecular Engineering～
September 30, 2025
Investor
Notice of the 28th Annual General Meeting of Shareholders
September 25, 2025
Investor
Consolidated Financial Results for the Year Ended July 31, 2025 (Based on Japanese GAAP)
September 24, 2025
Research and Development
“ALAgene® technology”-Derived Antibody Therapeutic Candidate Achieves Phase I Clinical Milestone ～Driving Future Growth through Strategic License Agreement～
September 19, 2025
Investor
Notice Regarding the Board of Directors’ Opinion on a Shareholder Proposal
September 19, 2025
Investor
Notice Regarding Partial Amendments to the Articles of Incorporation
September 11, 2025
Investor
[Summary] Consolidated Financial Results for the Fiscal Year Ended July 31, 2025 (Under Japanese GAAP)
September 8, 2025
Investor
Notice Regarding Revision of Full-Year Financial Results Forecast for the Fiscal Year Ended July 2025
September 8, 2025
Investor
Notice Regarding Special Loss (non-consolidated) due to Impairment of Investment in a Subsidiary
November 13, 2025
Research and Development
Pharma Foods Partners with The University of Tokyo For Next-Generation Antibody Drug Discovery ～A Leap Forward with AI and Advanced Molecular Engineering～
September 30, 2025
Investor
Notice of the 28th Annual General Meeting of Shareholders
September 25, 2025
Investor
Consolidated Financial Results for the Year Ended July 31, 2025 (Based on Japanese GAAP)
September 24, 2025
Research and Development
“ALAgene® technology”-Derived Antibody Therapeutic Candidate Achieves Phase I Clinical Milestone ～Driving Future Growth through Strategic License Agreement～
September 19, 2025
Investor
Notice Regarding the Board of Directors’ Opinion on a Shareholder Proposal
September 19, 2025
Investor
Notice Regarding Partial Amendments to the Articles of Incorporation
September 11, 2025
Investor
[Summary] Consolidated Financial Results for the Fiscal Year Ended July 31, 2025 (Under Japanese GAAP)
September 8, 2025
Investor
Notice Regarding Revision of Full-Year Financial Results Forecast for the Fiscal Year Ended July 2025
September 8, 2025
Investor
Notice Regarding Special Loss (non-consolidated) due to Impairment of Investment in a Subsidiary